Ex vivo induced regulatory human/murine mesenchymal stem cells as immune modulators

Stem Cells

Volumn 33, Issue 7, 2015, Pages 2256-2267

  Hinden, Liad ^a   Shainer, Reut ^a   Almogi Hazan, Osnat ^a   Or, Reuven ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Cell therapy; Immune disorders; Immunomodulation; Mesenchymal stem cells

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CYCLOOXYGENASE 2; GAMMA INTERFERON; HEME OXYGENASE 1; INDOLEAMINE 2,3 DIOXYGENASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; KYNURENINE; LEUKEMIA INHIBITORY FACTOR; PROGRAMMED DEATH 1 LIGAND 1; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FUNCTION; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASES; DOWN REGULATION; EX VIVO STUDY; FEMALE; GENE EXPRESSION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VIVO STUDY; LYMPHOCYTE DIFFERENTIATION; MALE; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; PHENOTYPE; PROPHYLAXIS; PROTEIN EXPRESSION; STEM CELL CULTURE; SURVIVAL; T CELL CULTURE; TH17 CELL; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BIOLOGICAL THERAPY; C57BL MOUSE; CELL DIFFERENTIATION; CYTOLOGY; DISEASE MODEL; GENETICS; IMMUNOLOGY; MESENCHYMAL STROMA CELL; PROCEDURES;

ANIMALS; CELL DIFFERENTIATION; CELL- AND TISSUE-BASED THERAPY; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOMODULATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL;

EID: 84931575022     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.2026     Document Type: Article

References (101)

1. da Silva Meirelles L, Chagastelles PC, Nardi NB,. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 2006; 119: 2204-2213.
2. Im GI, Shin YW, Lee KB,. Do adipose tissue-derived mesenchymal stem cells have the same osteogenic and chondrogenic potential as bone marrow-derived cells? Osteoarthr Cartil 2005; 13: 845-853.
3. In 't Anker PS, Scherjon SA, Kleijburg-van der Keur C, et al., Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells 2004; 22: 1338-1345.
4. Wang HS, Hung SC, Peng ST, et al., Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. STEM CELLS 2004; 22: 1330-1337.
5. Le Blanc K, Tammik C, Rosendahl K, et al., HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003; 31: 890-896.
6. Le Blanc K, Mougiakakos D,. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol 2012; 12: 383-396.
7. Rasmusson I, Uhlin M, Le Blanc K, et al., Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes. J Leukoc Biol 2007; 82: 887-893.
8. Rasmusson I, Ringden O, Sundberg B, et al., Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res 2005; 305: 33-41.
9. Sundin M, Barrett AJ, Ringden O, et al., HSCT recipients have specific tolerance to MSC but not to the MSC donor. J Immunother 2009; 32: 755-764.
10. Aggarwal S, Pittenger MF,. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-1822.
11. Glennie S, Soeiro I, Dyson PJ, et al., Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005; 105: 2821-2827.
12. English K, Ryan JM, Tobin L, et al., Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol 2009; 156: 149-160.
13. Glenn JD, Smith MD, Calabresi PA, et al., Mesenchymal stem cells differentially modulate effector CD8+ T cell subsets and exacerbate experimental autoimmune encephalomyelitis. STEM CELLS 2014; 32: 2744-2755.
14. Ghannam S, Pene J, Torcy-Moquet G, et al., Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol 2010; 185: 302-312.
15. Luz-Crawford P, Noel D, Fernandez X, et al., Mesenchymal stem cells repress Th17 molecular program through the PD-1 pathway. PLoS One 2012; 7: e45272.
16. Sato K, Ozaki K, Oh I, et al., Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007; 109: 228-234.
17. Li W, Ren G, Huang Y, et al., Mesenchymal stem cells: A double-edged sword in regulating immune responses. Cell Death Differ 2012; 19: 1505-1513.
18. Najar M, Raicevic G, Boufker HI, et al., Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources. Cell Immunol 2010; 264: 171-179.
19. Mougiakakos D, Jitschin R, Johansson CC, et al., The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood 2011; 117: 4826-4835.
20. Ryan JM, Barry F, Murphy JM, et al., Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 2007; 149: 353-363.
21. Francois M, Romieu-Mourez R, Li M, et al., Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther 2012; 20: 187-195.
22. Sheng H, Wang Y, Jin Y, et al., A critical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Res 2008; 18: 846-857.
23. Chinnadurai R, Copland IB, Patel SR, et al., IDO-independent suppression of T cell effector function by IFN-gamma-licensed human mesenchymal stromal cells. J Immunol 2014; 192: 1491-1501.
24. Ren G, Su J, Zhang L, et al., Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. STEM CELLS 2009; 27: 1954-1962.
25. Meisel R, Brockers S, Heseler K, et al., Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase. Leukemia 2011; 25: 648-654.
26. Le Blanc K, Frassoni F, Ball L, et al., Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 2008; 371: 1579-1586.
27. Perez-Simon JA, Lopez-Villar O, Andreu EJ, et al., Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: Results of a phase I/II clinical trial. Haematologica 2011; 96: 1072-1076.
28. Prasad VK, Lucas KG, Kleiner GI, et al., Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant 2011; 17: 534-541.
29. Liang J, Zhang H, Hua B, et al., Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: A pilot clinical study. Ann Rheum Dis 2010; 69: 1423-1429.
30. Tan J, Wu W, Xu X, et al., Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: A randomized controlled trial. JAMA 2012; 307: 1169-1177.
31. Yamout B, Hourani R, Salti H, et al., Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: A pilot study. J Neuroimmunol 2010; 227: 185-189.
32. Lee PH, Lee JE, Kim HS, et al., A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann Neurol 2012; 72: 32-40.
33. Lee PH, Kim JW, Bang OY, et al., Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. Clin Pharmacol Ther 2008; 83: 723-730.
34. Connick P, Kolappan M, Crawley C, et al., Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: An open-label phase 2a proof-of-concept study. Lancet Neurol 2012; 11: 150-156.
35. Forbes GM, Sturm MJ, Leong RW, et al., A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy. Clin Gastroenterol Hepatol 2014; 12: 64-71.
36. Wang D, Zhang H, Liang J, et al., Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience. Cell Transplant 2013; 22: 2267-2277.
37. Knyazev OV, Parfenov AI, Shcherbakov PL, et al., Cell therapy of refractory Crohn's disease. Bull Exp Biol Med 2013; 156: 139-145.
38. Figueroa FE, Carrion F, Villanueva S, et al., Mesenchymal stem cell treatment for autoimmune diseases: A critical review. Biol Res 2012; 45: 269-277.
39. Casiraghi F, Perico N, Remuzzi G,. Mesenchymal stromal cells to promote solid organ transplantation tolerance. Curr Opin Organ Transplant 2013; 18: 51-58.
40. Wang S, Qu X, Zhao RC,. Clinical applications of mesenchymal stem cells. J Hematol Oncol 2012; 5: 19.
41. Ankrum J, Karp JM,. Mesenchymal stem cell therapy: Two steps forward, one step back. Trends Mol Med 2010; 16: 203-209.
42. Allison M,. Genzyme backs Osiris, despite Prochymal flop. Nat Biotechnol 2009; 27: 966-967.
43. Kim N, Im KI, Lim JY, et al., Mesenchymal stem cells for the treatment and prevention of graft-versus-host disease: Experiments and practice. Ann Hematol 2013; 92: 1295-1308.
44. Galipeau J,. The mesenchymal stromal cells dilemma-Does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Cytotherapy 2013; 15: 2-8.
45. Svobodova E, Krulova M, Zajicova A, et al., The role of mouse mesenchymal stem cells in differentiation of naive T-cells into anti-inflammatory regulatory T-cell or proinflammatory helper T-cell 17 population. Stem Cells Dev 2012; 21: 901-910.
46. Romieu-Mourez R, Francois M, Boivin MN, et al., Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. J Immunol 2009; 182: 7963-7973.
47. Stagg J, Pommey S, Eliopoulos N, et al., Interferon-gamma-stimulated marrow stromal cells: A new type of nonhematopoietic antigen-presenting cell. Blood 2006; 107: 2570-2577.
48. Polchert D, Sobinsky J, Douglas G, et al., IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 2008; 38: 1745-1755.
49. Romieu-Mourez R, Francois M, Boivin MN, et al., Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-gamma, TGF-beta, and cell density. J Immunol 2007; 179: 1549-1558.
50. Francois M, Romieu-Mourez R, Stock-Martineau S, et al., Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties. Blood 2009; 114: 2632-2638.
51. Mellor AL, Munn DH,. IDO expression by dendritic cells: Tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4: 762-774.
52. Jasperson LK, Bucher C, Panoskaltsis-Mortari A, et al., Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality. Blood 2009; 114: 5062-5070.
53. Nguyen NT, Kimura A, Nakahama T, et al., Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci USA 2010; 107: 19961-19966.
54. Mezrich JD, Fechner JH, Zhang X, et al., An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol 2010; 185: 3190-3198.
55. Resnick IB, Barkats C, Shapira MY, et al., Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC). Am J Blood Res 2013; 3: 225-238.
56. Azar Y, Shainer R, Almogi-Hazan O, et al., Preimplantation factor reduces graft-versus-host disease by regulating immune response and lowering oxidative stress (murine model). Biol Blood Marrow Transplant 2013; 19: 519-528.
57. Samuel S, Azar Y, Corchia N, et al., Improved immune function with donor B-cell infusion after semi-allogeneic bone marrow transplantation in mice. Arch Med Res 2008; 39: 61-68.
58. Przepiorka D, Weisdorf D, Martin P, et al., 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
59. Plumas J, Chaperot L, Richard MJ, et al., Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia 2005; 19: 1597-1604.
60. Ge W, Jiang J, Arp J, et al., Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation 2010; 90: 1312-1320.
61. Ren G, Zhang L, Zhao X, et al., Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2: 141-150.
62. Fritsche E, Schafer C, Calles C, et al., Lightening up the UV response by identification of the arylhydrocarbon receptor as a cytoplasmatic target for ultraviolet B radiation. Proc Natl Acad Sci USA 2007; 104: 8851-8856.
63. Kimura A, Naka T, Nakahama T, et al., Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses. J Exp Med 2009; 206: 2027-2035.
64. Gao W, Thompson L, Zhou Q, et al., Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6. Cell Cycle 2009; 8: 1444-1450.
65. Park J, Gao W, Whiston R, et al., Modulation of CD4+ T lymphocyte lineage outcomes with targeted, nanoparticle-mediated cytokine delivery. Mol Pharm 2011; 8: 143-152.
66. Kappel LW, Goldberg GL, King CG, et al., IL-17 contributes to CD4-mediated graft-versus-host disease. Blood 2009; 113: 945-952.
67. Dander E, Balduzzi A, Zappa G, et al., Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation. Transplantation 2009; 88: 1261-1272.
68. Ratajczak P, Janin A, Peffault de Latour R, et al., Th17/Treg ratio in human graft-versus-host disease. Blood 2010; 116: 1165-1171.
69. Newell LF, Deans RJ, Maziarz RT,. Adult adherent stromal cells in the management of graft-versus-host disease. Exp Opin Biol Ther 2014; 14: 231-246.
70. Li H, Guo Z, Jiang X, et al., Mesenchymal stem cells alter migratory property of T and dendritic cells to delay the development of murine lethal acute graft-versus-host disease. STEM CELLS 2008; 26: 2531-2541.
71. Baron F, Lechanteur C, Willems E, et al., Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant 2010; 16: 838-847.
72. Macmillan ML, Blazar BR, DeFor TE, et al., Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: Results of a phase I-II clinical trial. Bone Marrow Transplant 2009; 43: 447-454.
73. Muller I, Kordowich S, Holzwarth C, et al., Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol Dis 2008; 40: 25-32.
74. Liu K, Chen Y, Zeng Y, et al., Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells Dev 2011; 20: 1679-1685.
75. Sun L, Akiyama K, Zhang H, et al., Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 2009; 27: 1421-1432.
76. Terness P, Bauer TM, Rose L, et al., Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: Mediation of suppression by tryptophan metabolites. J Exp Med 2002; 196: 447-457.
77. Jasperson LK, Bucher C, Panoskaltsis-Mortari A, et al., Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality. Blood 2008; 111: 3257-3265.
78. Bauer TM, Jiga LP, Chuang JJ, et al., Studying the immunosuppressive role of indoleamine 2,3-dioxygenase: Tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivo. Transpl Int 2005; 18: 95-100.
79. Frumento G, Rotondo R, Tonetti M, et al., Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 2002; 196: 459-468.
80. Radu CA, Bosch N, Bauer TM, et al., Immunosuppressive effect of tryptophan metabolites in composite tissue allotransplantation. Plast Reconstr Surg 2007; 119: 2023-2028.
81. Soria G, Ben-Baruch A,. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 2008; 267: 271-285.
82. Kobayashi Y,. The role of chemokines in neutrophil biology. Front Biosci 2008; 13: 2400-2407.
83. Dufour JH, Dziejman M, Liu MT, et al., IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 2002; 168: 3195-3204.
84. Cole KE, Strick CA, Paradis TJ, et al., Interferon-inducible T cell alpha chemoattractant (I-TAC): A novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 1998; 187: 2009-2021.
85. Omatsu Y, Seike M, Sugiyama T, et al., Foxc1 is a critical regulator of haematopoietic stem/progenitor cell niche formation. Nature 2014; 508: 536-540.
86. Chitteti BR, Bethel M, Kacena MA, et al., CD166 and regulation of hematopoiesis. Curr Opin Hematol 2013; 20: 273-280.
87. Chitteti BR, Kobayashi M, Cheng Y, et al., CD166 regulates human and murine hematopoietic stem cells and the hematopoietic niche. Blood 2014; 124: 519-529.
88. Greenbaum A, Hsu YM, Day RB, et al., CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature 2013; 495: 227-230.
89. Gavalas NG, Tsiatas M, Tsitsilonis O, et al., VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. Br J Cancer 2012; 107: 1869-1875.
90. Weinberg JB,. Nitric oxide synthase 2 and cyclooxygenase 2 interactions in inflammation. Immunol Res 2000; 22: 319-341.
91. Aisemberg J, Vercelli C, Billi S, et al., Nitric oxide mediates prostaglandins' deleterious effect on lipopolysaccharide-triggered murine fetal resorption. Proc Natl Acad Sci USA 2007; 104: 7534-7539.
92. Kim SF,. The role of nitric oxide in prostaglandin biology; update. Nitric Oxide 2011; 25: 255-264.
93. Hanieh H,. Toward understanding the role of aryl hydrocarbon receptor in the immune system: Current progress and future trends. Biomed Res Int 2014; 2014: 520763.
94. Vogel CF, Goth SR, Dong B, et al., Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase. Biochem Biophys Res Commun 2008; 375: 331-335.
95. Geremia A, Biancheri P, Allan P, et al., Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev 2014; 13: 3-10.
96. Cavalcante P, Bernasconi P, Mantegazza R,. Autoimmune mechanisms in myasthenia gravis. Curr Opin Neurol 2012; 25: 621-629.
97. Niu Q, Cai B, Huang ZC, et al., Disturbed Th17/Treg balance in patients with rheumatoid arthritis. Rheumatol Int 2012; 32: 2731-2736.
98. Shao S, He F, Yang Y, et al., Th17 cells in type 1 diabetes. Cell Immunol 2012; 280: 16-21.
99. Wang Q, Li H, Yao Y, et al., The overexpression of heparin-binding epidermal growth factor is responsible for Th17-induced airway remodeling in an experimental asthma model. J Immunol 2010; 185: 834-841.
100. Carlson MJ, West ML, Coghill JM, et al., In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood 2009; 113: 1365-1374.
101. Duffy MM, Pindjakova J, Hanley SA, et al., Mesenchymal stem cell inhibition of T-helper 17 cell- differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor. Eur J Immunol 2012; 41: 2840-2851.